ARS Pharmaceuticals, Inc. Prepaid Expense and Other Assets, Current
ARS Pharmaceuticals, Inc. (SPRY) had Prepaid Expense and Other Assets, Current of $9.14 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › and Other Assets
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-13
- 2026-06-30: Prepaid Expense and Other Assets, Current $9.14M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $6.79M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $6.19M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $6.42M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $9.14M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $6.79M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $6.19M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $7.44M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $11.56M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $6.89M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $2.68M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.99M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $2.61M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $3.37M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $2.56M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $2.83M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.80M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $3.32M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $4.17M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $5.15M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $7.49M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $667.00K 10-K · filed 2023-03-23 | $7.45M 10-K · filed 2022-03-31 |
| 2021-09-30 | $4.70M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $3.34M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $4.14M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $4.09M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |